Skip to main content
logo
Impact BioMedical Inc. (IBO)
NYSEAMERICAN: IBO · Real-Time Price · USD
4.840
-0.480 (-9.02%)
At close: Oct 5, 2026, 4:00 PM EDT
4.840
0.00 (0.00%)
Pre-market: Oct 6, 2026, 4:00 AM EDT

Impact BioMedical Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
0.79-11.84-24.71-4.34-7.05-1.3
Depreciation & Amortization
1.141.150.010.01--
Other Amortization
--1.111.111.111.11
Loss (Gain) From Sale of Assets
0.010.01----
Asset Writedown & Restructuring Costs
--25.36---
Loss (Gain) From Sale of Investments
----4.1-
Stock-Based Compensation
1.450.20.02---
Other Operating Activities
-5.477.99-4.03-0.07-0.83-1.94
Change in Accounts Receivable
--00.13-0.13--
Change in Inventory
0.010.01----
Change in Accounts Payable
0.750.47-0.440.290.420.11
Change in Other Net Operating Assets
0.810.12-0.30.27-0-0
Operating Cash Flow
-0.51-1.89-2.85-2.85-2.24-2.03
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
----0.02-0.28-
Investment in Securities
-----0.07-4.18
Other Investing Activities
0000-0.01-5.28
Investing Cash Flow
000-0.02-0.35-9.46

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-0.181.12-2.5511.46
Long-Term Debt Issued
---2.87--
Total Debt Issued
0.180.181.122.872.5511.46
Short-Term Debt Repaid
--0.29----
Total Debt Repaid
-0.29-0.29----
Net Debt Issued (Repaid)
-0.11-0.111.122.872.5511.46
Issuance of Common Stock
--3.73---
Financing Cash Flow
-0.11-0.114.852.872.5511.46

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Miscellaneous Cash Flow Adjustments
------0
Net Cash Flow
-0.61-22-0-0.04-0.03

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-0.51-1.89-2.85-2.87-2.52-2.03
Free Cash Flow Growth
------
Free Cash Flow Margin
-1451.43%-5906.25%---5036.00%-
Free Cash Flow Per Share
-0.08-0.76-3.35-0.60-0.45-0.36
Levered Free Cash Flow
1.02-1.52-1.92-1.44-0.98-1.16
Unlevered Free Cash Flow
1.18-1.02-1.26-1.17-0.69-0.97

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
1.560.6-0.610.440.420.1
SEC Filings: 10-K · 10-Q